Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study
Authors' conclusion
Precise imaging evaluation of the initial RAI therapy may help predict the prognosis during the first 5 years, contributing to more effective comprehensive treatment approaches for long-term management.
Study context
- Population
- Thyroid cancer patients receiving initial therapeutic radioactive iodine (RAI) after total thyroidectomy, 2010–2021
- Participants
- 290 patients
- Exposure
- Non-DM vs RAI-non-avid DM vs RAI-avid DM, classified by initial RAI therapy imaging
- Outcome
- PFS and overall survival
Main finding
As reported in the abstract
Survival rates · 5-year to 7-year
Non-DM
98% to 95%
RAI-non-avid DM
86% to 78%
RAI-avid DM
82% to 82%
Observational data: associations, not effects.
Further findings
- Average count of 131I-avid area was a significant prognostic factor for progression-free survival (PFS), independent of age, distant metastatic pattern, histological subtype and T classification
- Site of metastases was a strong prognostic determinant
- Retreatment was preferably performed within 2 years after initial RAI therapy, a period that appears critical for efficacy
Original publication
Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study. J Clin Endocrinol Metab. Published 15 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →